Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Public ClinicalTrials.gov record NCT05735080. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer
Study identification
- NCT ID
- NCT05735080
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Incyclix Bio
- Industry
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
- Abemaciclib Drug
- Fulvestrant Drug
- INX-315 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2023
- Primary completion
- Jun 30, 2027
- Completion
- Aug 31, 2027
- Last update posted
- Mar 31, 2026
2023 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists | Orlando | Florida | 32827 | Recruiting |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30322 | Recruiting |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | Recruiting |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46804 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | Recruiting |
| Levine Cancer Institute (LCI)- Atrium Health | Charlotte | North Carolina | 28204 | Recruiting |
| Duke Cancer Center/ DUMC | Durham | North Carolina | 27705 | Recruiting |
| Gabrail Cancer Research Center | Canton | Ohio | 44718 | Recruiting |
| Next Oncology | Dallas | Texas | 75039 | Recruiting |
| UTSW Medical Center | Dallas | Texas | 75390 | Recruiting |
| Oncology Consultants | Houston | Texas | 77030 | Not yet recruiting |
| Next Oncology | Houston | Texas | 77054 | Recruiting |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05735080, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05735080 live on ClinicalTrials.gov.